David Mulham - USANA Health Chief Field Development Officer
| USNA Stock | USD 39.90 0.54 1.37% |
Executive
Mr. David Mulham is Chief Field Development Officer of the Company. Mr. Mulham joined USANA in 2009 as Field Development, Marketing and Customer Service Manager for Australia and New Zealand. In February 2011, he was appointed General Manager, for Australia and New Zealand and served in that role until June 2011, when he was appointed Vice President, Pacific Region . In February 2014 he was appointed Executive Vice President of Field Development, Pacific Region and then in May 2015 he was appointed Executive Vice President, Pacific Region. He served in that role until January 2016 when he was appointed Executive Vice President, Pacific and Europe and then in September 2016, he was appointed Executive Vice President, the Americas, Pacific and Europe. He served in that role until February 2017, when he was appointed Chief Field Development Officer and this title was later changed to Chief Sales Officer. Prior to joining USANA, Mr. Mulham had extensive experience in the Direct Selling Industry having worked for Amway, Mary Kay, Nutri Metics and Dorling Kindersley Family Learning. He subsequently worked in property development as Director of both Hunter Valley Gardens and Tempus Two Winery. Mr. Mulham has a post graduate diploma from Macquarie Graduate School of Management, Sydney, and received the Silver Stevie Award in 2015, for Executive of the YearHealth Products Services and Pharmaceuticals. since 2021.
| Age | 64 |
| Tenure | 3 years |
| Address | 3838 West Parkway Boulevard, Salt Lake City, UT, United States, 84120 |
| Phone | 801 954 7100 |
| Web | https://www.usana.com |
USANA Health Management Efficiency
The company has return on total asset (ROA) of 0.0809 % which means that it generated a profit of $0.0809 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1083 %, meaning that it created $0.1083 on every $100 dollars invested by stockholders. USANA Health's management efficiency ratios could be used to measure how well USANA Health manages its routine affairs as well as how well it operates its assets and liabilities. At present, USANA Health's Return On Tangible Assets are projected to slightly decrease based on the last few years of reporting. The current year's Return On Assets is expected to grow to 0.25, whereas Return On Capital Employed is forecasted to decline to 0.26. At present, USANA Health's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 57.6 M, whereas Non Current Assets Total are forecasted to decline to about 110.8 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Sally Abbott | Post Holdings | N/A | |
| James Valentine | John B Sanfilippo | 60 | |
| P Aquino | Treehouse Foods | N/A | |
| Chris Cole | Bridgford Foods | N/A | |
| Robyn Marshall | John B Sanfilippo | N/A | |
| Howard CPA | Central Garden Pet | 61 | |
| Curt Craig | Treehouse Foods | 52 | |
| Mary Kehoe | J J Snack | 62 | |
| Lynwood Mallard | J J Snack | 55 | |
| Joyce McCarthy | Central Garden Pet | 54 | |
| Friederike Edelmann | Central Garden Pet | N/A | |
| Steve Landry | Treehouse Foods | 59 | |
| Amiee Castleberry | Seneca Foods Corp | N/A | |
| Luis Viso | Lancaster Colony | 63 | |
| Steve Schonhoff | Post Holdings | N/A | |
| Linda Zink | Simply Good Foods | 59 | |
| Mike McCoy | Post Holdings | N/A | |
| Ken Elsbury | Central Garden Pet | N/A | |
| Michael Bridgford | Bridgford Foods | 42 | |
| Amy Held | Simply Good Foods | 50 | |
| Jill Clark | Simply Good Foods | 55 | |
Management Performance
| Return On Equity | 0.11 | ||||
| Return On Asset | 0.0809 |
USANA Health Sciences Leadership Team
Elected by the shareholders, the USANA Health's board of directors comprises two types of representatives: USANA Health inside directors who are chosen from within the company, and outside directors, selected externally and held independent of USANA. The board's role is to monitor USANA Health's management team and ensure that shareholders' interests are well served. USANA Health's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, USANA Health's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Timothy Wood, Independent Director | ||
| Andrew Masuda, Director Relations | ||
| Patrique Richards, Executive Development | ||
| Paul Jones, CFO, Principal Accounting Officer and Chief Leadership Devel. Officer | ||
| Peggie Pelosi, Independent Director | ||
| Frederic Winssinger, Independent Director | ||
| Joshua Foukas, General Officer | ||
| Peter Benedict, Chief Officer | ||
| Douglas Hekking, Chief Officer | ||
| John Cuomo, Executive Technology | ||
| Walter Noot, Chief Operating Officer | ||
| Brian Dixon, Executive Education | ||
| P Foukas, Chief Legal Officer, General Counsel and Corporate Secretary | ||
| Feng Peng, Independent Director | ||
| Kevin Guest, Chairman of the Board, Chief Executive Officer | ||
| Xia Ding, Independent Director | ||
| Daniel Macuga, Chief Communications and Marketing Officer | ||
| Robert Anciaux, Independent Director | ||
| David Mulham, Chief Field Development Officer | ||
| Gilbert Fuller, Lead Independent Director | ||
| Myron Wentz, Founder and Chairman | ||
| John Fleming, Independent Director | ||
| Joshua JD, General Officer | ||
| Jim Brown, Chief Production Officer | ||
| Brent Neidig, Chief Officer and Managing Director of China | ||
| G Hekking, Chief Financial Officer | ||
| Robert Sinnott, Chief Scientific Officer | ||
| Dr MNS, Chief Officer |
USANA Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is USANA Health a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.11 | ||||
| Return On Asset | 0.0809 | ||||
| Profit Margin | 0.06 % | ||||
| Operating Margin | 0.08 % | ||||
| Current Valuation | 433.46 M | ||||
| Shares Outstanding | 19.06 M | ||||
| Shares Owned By Insiders | 41.70 % | ||||
| Shares Owned By Institutions | 57.55 % | ||||
| Number Of Shares Shorted | 516.56 K | ||||
| Price To Earning | 8.70 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether USANA Health Sciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of USANA Health's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Usana Health Sciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Usana Health Sciences Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in USANA Health Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Personal Care Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of USANA Health. If investors know USANA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about USANA Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.06) | Earnings Share 2.83 | Revenue Per Share 45.085 | Quarterly Revenue Growth (0.06) | Return On Assets 0.0809 |
The market value of USANA Health Sciences is measured differently than its book value, which is the value of USANA that is recorded on the company's balance sheet. Investors also form their own opinion of USANA Health's value that differs from its market value or its book value, called intrinsic value, which is USANA Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because USANA Health's market value can be influenced by many factors that don't directly affect USANA Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between USANA Health's value and its price as these two are different measures arrived at by different means. Investors typically determine if USANA Health is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, USANA Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.